Evidence map›Paper›PMID 39402419›Full record

SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Harnessing hematological ratios: prognostic insights for breast cancer management.

Carolina Coradi, Carolina Panis

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Carolina Coradi *Laboratory of Tumor Biology, Centro de Ciências da Saúde, Universidade Estadual do Oeste do Paraná, Rodovia Vitório Traiano, Km2, Francisco Beltrão, Paraná, Brazil.
Carolina Panis *Laboratory of Tumor Biology, Centro de Ciências da Saúde, Universidade Estadual do Oeste do Paraná, Rodovia Vitório Traiano, Km2, Francisco Beltrão, Paraná, Brazil. carolpanis@hotmail.com.ORCID http://orcid.org/0000-0002-0104-4369

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 305335/2021-9Conselho Nacional de Desenvolvimento Científico e Tecnológico 402364/2021-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 441017/2023-1
6 · The paper itself

Abstract

backgroundBreast cancer is one of the most lethal diseases affecting women globally. Its progression is influenced by various factors, including the immune system's ability to combat cancer cells. While hematological indices have been recognized as valuable biomarkers for monitoring patients with different types of neoplasms, there remains a considerable gap in research concerning their application in breast cancer. MATERIAL AND

methodsTo address this, we conducted a systematic review of studies examining hematological indices as prognostic predictors in breast cancer patients.

resultsThe majority of studies demonstrate a significant correlation between these indices and survival outcomes, underscoring their potential utility in patient monitoring.

conclusionsHematological-based indexes can be valuable tools for monitoring breast cancer, especially those ongoing poor prognosis scenarios.

Indexed as

Biomarkers, TumorBreast NeoplasmsFemaleHumansPrognosisBiomarkers, TumorBreast neoplasmsHematological ratiosLeukocyte count

Identifiers

PMID39402419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.